Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  HIV Infection

  Free Subscription


09.09.2024

5 AIDS
1 AIDS Res Hum Retroviruses
2 Am J Epidemiol
2 Antimicrob Agents Chemother
2 Clin Infect Dis
4 HIV Med
1 J Acquir Immune Defic Syndr
3 J Infect Dis
1 J Med Virol
3 J Virol
1 Lancet
1 Nat Med
1 Nature
13 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. ZANIEWSKI E, Skrivankova VW, Brazier E, Avihingsanon A, et al
    Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.
    AIDS. 2024 Sep 5. doi: 10.1097/QAD.0000000000004007.
    PubMed         Abstract available

  2. EUSTAQUIO PC, Burnett J, Prejean J, Chapin-Bardales J, et al
    Changes in HIV Pre-exposure Prophylaxis Awareness and Use Among Males Who Inject Drugs Who Have Sex with Men by Sexual Identity, 19 US Urban Areas, 2018 & 2022.
    AIDS. 2024 Sep 3. doi: 10.1097/QAD.0000000000004005.
    PubMed         Abstract available

  3. ZHAO R, Sanstead E, Alarid-Escudero F, Huchko M, et al
    Primary HPV screening compared with other cervical cancer screening strategies in women with HIV: a cost-effectiveness study.
    AIDS. 2024 Sep 2. doi: 10.1097/QAD.0000000000004002.
    PubMed         Abstract available

  4. RUDERMAN SA, Willig AL, Cleveland JD, Burkholder G, et al
    Low food security is associated with frailty status and frailty components among people with HIV.
    AIDS. 2024 Sep 4. doi: 10.1097/QAD.0000000000004006.
    PubMed         Abstract available

  5. FILIP I
    Perinatal exposure to HIV leaves a lasting neurocognitive mark - even when vertical transmission is prevented.
    AIDS. 2024 Sep 2. doi: 10.1097/QAD.0000000000004004.
    PubMed        


    AIDS Res Hum Retroviruses

  6. WALMSLEY S
    Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for AIDS Research and Human Retroviruses.
    AIDS Res Hum Retroviruses. 2024;40:501.
    PubMed        


    Am J Epidemiol

  7. TORDOFF DM, Minalga B, Cathain NO, Fernandez A, et al
    Comparing Two-Step Approaches to Measuring Gender Identity: The Reliability and Applications of Asking About Sex Assigned at Birth versus Transgender Self-Identification.
    Am J Epidemiol. 2024 Sep 3:kwae341. doi: 10.1093.
    PubMed         Abstract available

  8. ZIVICH PN, Cole SR, Edwards JK, Shook-Sa BE, et al
    Bridged Treatment Comparisons: an Illustrative Application in HIV Treatment.
    Am J Epidemiol. 2024 Aug 31:kwae340. doi: 10.1093.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  9. SHIN Y, Park CM, Kim D-E, Kim S, et al
    Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.
    Antimicrob Agents Chemother. 2024 Sep 4:e0064324. doi: 10.1128/aac.00643.
    PubMed         Abstract available

  10. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
    Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
    PubMed         Abstract available


    Clin Infect Dis

  11. ANDERSON D, Ramgopal M, Hagins DP, Lee J, et al
    DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain.
    Clin Infect Dis. 2024 Sep 4:ciae449. doi: 10.1093.
    PubMed         Abstract available

  12. EKE AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, et al
    Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.
    Clin Infect Dis. 2024 Sep 2:ciae441. doi: 10.1093.
    PubMed         Abstract available


    HIV Med

  13. PREVOTEAU DU CLARY F, Majerholc C, Zucman D, Livrozet JM, et al
    Evaluation of HIV antiretroviral treatment adherence in 2019 using anonymized data from the French national health insurance claims data base: The COCOVIH study.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13690.
    PubMed         Abstract available

  14. PINEIRO C, Policarpo S, Caldas C, Santos L, et al
    Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.
    HIV Med. 2024 Sep 6. doi: 10.1111/hiv.13699.
    PubMed         Abstract available

  15. MCCALL KL, Cabral DL, Coghlan JF, Concepcion AM, et al
    Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024.
    HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13709.
    PubMed         Abstract available

  16. SHU Y, Zhang M, Li J, Deng X, et al
    Trajectories of CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio in patients with HIV and long-term virological suppression based on Yunnan HIV cohort.
    HIV Med. 2024 Sep 2. doi: 10.1111/hiv.13707.
    PubMed         Abstract available


    J Acquir Immune Defic Syndr

  17. BATOHI N, Shalekoff S, Martinson NA, Ebrahim O, et al
    HIV-1 Elite Controllers are Characterised by Elevated Levels of CD69-Expressing Natural Killer Cells.
    J Acquir Immune Defic Syndr. 2024 Sep 2. doi: 10.1097/QAI.0000000000003518.
    PubMed         Abstract available


    J Infect Dis

  18. WALKER NF, Schutz C, Ward A, Barr D, et al
    Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis.
    J Infect Dis. 2024 Sep 2:jiae296. doi: 10.1093.
    PubMed         Abstract available

  19. JANES H, Fisher LH, Kee JJ, Parameswaran L, et al
    Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
    J Infect Dis. 2024 Sep 3:jiae400. doi: 10.1093.
    PubMed         Abstract available

  20. DE SCHEERDER MA, Degroote S, Delporte M, Kiselinova M, et al
    In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).
    J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093.
    PubMed         Abstract available


    J Med Virol

  21. LO VT, Lim HA, Jang SS, Kim MC, et al
    N121T and N121S substitutions on the SARS-CoV-2 spike protein impact on serum neutralization.
    J Med Virol. 2024;96:e29871.
    PubMed         Abstract available


    J Virol

  22. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    PubMed         Abstract available

  23. TAUZIN A, Marchitto L, Belanger E, Benlarbi M, et al
    Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
    J Virol. 2024 Sep 4:e0096024. doi: 10.1128/jvi.00960.
    PubMed         Abstract available

  24. ZHANG W, Nilles TL, Bream JH, Li H, et al
    Breadth and polyfunctionality of T cell responses to human cytomegalovirus in men who have sex with men: relationship with HIV infection and frailty.
    J Virol. 2024 Sep 4:e0116724. doi: 10.1128/jvi.01167.
    PubMed         Abstract available


    Lancet

  25. KIZITO S, Nabayinda J, Nabunya P, Ssewamala FM, et al
    HIV and tuberculosis in Uganda: are we neglecting poverty?
    Lancet. 2024;404:844-845.
    PubMed        


    Nat Med

  26. SAEZ-CIRION A, Mamez AC, Avettand-Fenoel V, Nabergoj M, et al
    Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.
    Nat Med. 2024 Sep 2. doi: 10.1038/s41591-024-03277.
    PubMed         Abstract available


    Nature

  27. KWON D
    HIV: how close are we to a vaccine - or a cure?
    Nature. 2024 Sep 2. doi: 10.1038/d41586-024-02840.
    PubMed        


    PLoS One

  28. LUWAYA EL, Mwape L, Bwalya K, Siakabanze C, et al
    Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
    PLoS One. 2024;19:e0308869.
    PubMed         Abstract available

  29. LI X, Trovao NS
    The evolutionary and transmission dynamics of HIV-1 CRF08_BC.
    PLoS One. 2024;19:e0310027.
    PubMed         Abstract available

  30. WILLIAMSON BD, Wu L, Huang Y, Hudson A, et al
    Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.
    PLoS One. 2024;19:e0310042.
    PubMed         Abstract available

  31. MIRZAEI H, Iranpour A, Esmaeilzadeh F, Barouni M, et al
    Cost-effectiveness of pretreatment HIV drug resistance testing in people living with HIV in Iran.
    PLoS One. 2024;19:e0309528.
    PubMed         Abstract available

  32. CASALINI C, Yeiser S, Amanuel H, Gottlieb A, et al
    Are children of key population individuals at higher risk of HIV than other children? Results from a multi-country analysis of routine program data.
    PLoS One. 2024;19:e0309847.
    PubMed         Abstract available

  33. SIQITHI S, Durojaiye OC, Adeniyi OV
    Effects of the timing of maternal antiretroviral therapy initiation, CD4 count, and HIV viral load on birth outcomes in the Eastern Cape province of South Africa: A secondary data analysis.
    PLoS One. 2024;19:e0308374.
    PubMed         Abstract available

  34. MAUEIA C, Murahwa A, Manjate A, Sacarlal J, et al
    The relationship between selected sexually transmitted pathogens, HPV and HIV infection status in women presenting with gynaecological symptoms in Maputo City, Mozambique.
    PLoS One. 2024;19:e0307781.
    PubMed         Abstract available

  35. LI J, Shen C, Liu ZW, Pu FL, et al
    Chinese herbal medicine for patients living with HIV in Guangxi province, China: A propensity score matching analysis of real-world data.
    PLoS One. 2024;19:e0304332.
    PubMed         Abstract available

  36. SEIFU BL, Fente BM, Melkam M, Asmare ZA, et al
    Determinants of care-seeking behavior for sexually transmitted infections among sexually active men in East Africa: A multilevel mixed effect analysis.
    PLoS One. 2024;19:e0307755.
    PubMed         Abstract available

  37. MUKOSHA M, Hatcher A, Lubeya MK, Maposa I, et al
    Persistent hypertension among postpartum women with comorbid HIV and preeclampsia in Zambia.
    PLoS One. 2024;19:e0309915.
    PubMed         Abstract available

  38. BLAKE E, Stringham E, Sloan-Aagard C
    Concurrent disease burden from multiple infectious diseases and the influence of social determinants in the contiguous United States.
    PLoS One. 2024;19:e0293431.
    PubMed         Abstract available

  39. MEHLOMAKULU V, Mabaso M, Jooste S, Cloete A, et al
    Prevalence and factors associated with external HIV-related stigma in the South African population: Results from the 2017 population-based household survey.
    PLoS One. 2024;19:e0309694.
    PubMed         Abstract available

  40. MANGALA C, Takou D, Maulot-Bangola D, Beloumou G, et al
    HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon.
    PLoS One. 2024;19:e0305935.
    PubMed         Abstract available


    PLoS Pathog

  41. JENNINGS J, Bracey H, Hong J, Nguyen DT, et al
    The HIV-1 capsid serves as a nanoscale reaction vessel for reverse transcription.
    PLoS Pathog. 2024;20:e1011810.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  42. HATTORI SI, Bulut H, Hayashi H, Kishimoto N, et al
    Structural and virologic mechanism of the emergence of resistance to M(pro) inhibitors in SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2024;121:e2404175121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.